# Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

> **NCT02244944** · PHASE2 · TERMINATED · sponsor: **Gregory Graf, PhD** · enrollment: 2 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver Disease (NAFLD)

## Interventions

- **DRUG:** EZ-Urso combination therapy

## Key facts

- **NCT ID:** NCT02244944
- **Lead sponsor:** Gregory Graf, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Failure to recruit
- **Last updated:** 2018-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02244944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02244944, "Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02244944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*